Literature DB >> 24835989

Mutational context and diverse clonal development in early and late bladder cancer.

Iver Nordentoft1, Philippe Lamy1, Karin Birkenkamp-Demtröder1, Karey Shumansky2, Søren Vang1, Henrik Hornshøj1, Malene Juul1, Palle Villesen3, Jakob Hedegaard1, Andrew Roth2, Kasper Thorsen1, Søren Høyer4, Michael Borre5, Thomas Reinert1, Niels Fristrup5, Lars Dyrskjøt1, Sohrab Shah2, Jakob Skou Pedersen1, Torben F Ørntoft6.   

Abstract

Bladder cancer (or urothelial cell carcinoma [UCC]) is characterized by field disease (malignant alterations in surrounding mucosa) and frequent recurrences. Whole-genome, exome, and transcriptome sequencing of 38 tumors, including four metachronous tumor pairs and 20 superficial tumors, identified an APOBEC mutational signature in one-third. This was biased toward the sense strand, correlated with mean expression level, and clustered near breakpoints. A>G mutations were up to eight times more frequent on the sense strand (p<0.002) in [ACG]AT contexts. The patient-specific APOBEC signature was negatively correlated to repair-gene expression and was not related to clinicopathological parameters. Mutations in gene families and single genes were related to tumor stage, and expression of chromatin modifiers correlated with survival. Evolutionary and subclonal analyses of early/late tumor pairs showed a unitary origin, and discrete tumor clones contained mutated cancer genes. The ancestral clones contained Pik3ca/Kdm6a mutations and may reflect the field-disease mutations shared among later tumors.
Copyright © 2014 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24835989     DOI: 10.1016/j.celrep.2014.04.038

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  50 in total

Review 1.  Targeting Signaling Transduction Pathways in Bladder Cancer.

Authors:  Phillip H Abbosh; David J McConkey; Elizabeth R Plimack
Journal:  Curr Oncol Rep       Date:  2015-12       Impact factor: 5.075

Review 2.  Overcoming therapeutic resistance in glioblastoma: the way forward.

Authors:  Satoru Osuka; Erwin G Van Meir
Journal:  J Clin Invest       Date:  2017-02-01       Impact factor: 14.808

3.  Avoidance of APOBEC3B-induced mutation by error-free lesion bypass.

Authors:  James I Hoopes; Amber L Hughes; Lauren A Hobson; Luis M Cortez; Alexander J Brown; Steven A Roberts
Journal:  Nucleic Acids Res       Date:  2017-05-19       Impact factor: 16.971

Review 4.  Toward personalized management in bladder cancer: the promise of novel molecular taxonomy.

Authors:  Marie-Lisa Eich; Lars Dyrskjøt; George J Netto
Journal:  Virchows Arch       Date:  2017-04-21       Impact factor: 4.064

Review 5.  Molecular substratification of bladder cancer: moving towards individualized patient management.

Authors:  Anirban P Mitra
Journal:  Ther Adv Urol       Date:  2016-03-28

6.  Genomic Subtypes of Non-invasive Bladder Cancer with Distinct Metabolic Profile and Female Gender Bias in KDM6A Mutation Frequency.

Authors:  Carolyn D Hurst; Olivia Alder; Fiona M Platt; Alastair Droop; Lucy F Stead; Julie E Burns; George J Burghel; Sunjay Jain; Leszek J Klimczak; Helen Lindsay; Jo-An Roulson; Claire F Taylor; Helene Thygesen; Angus J Cameron; Anne J Ridley; Helen R Mott; Dmitry A Gordenin; Margaret A Knowles
Journal:  Cancer Cell       Date:  2017-11-13       Impact factor: 31.743

7.  Spatial and temporal clonal evolution during development of metastatic urothelial carcinoma.

Authors:  Mathilde B H Thomsen; Iver Nordentoft; Philippe Lamy; Søren Høyer; Søren Vang; Jakob Hedegaard; Michael Borre; Jørgen B Jensen; Torben F Ørntoft; Lars Dyrskjøt
Journal:  Mol Oncol       Date:  2016-08-17       Impact factor: 6.603

8.  LncRNA MALAT1 promotes tumor growth and metastasis by targeting miR-124/foxq1 in bladder transitional cell carcinoma (BTCC).

Authors:  Dechao Jiao; Zongming Li; Ming Zhu; Yanli Wang; Gang Wu; Xinwei Han
Journal:  Am J Cancer Res       Date:  2018-04-01       Impact factor: 6.166

9.  A multi-omics approach to understanding the field effect in bladder cancer.

Authors:  Xue Li; Ali Hashemi Gheinani; Rosalyn M Adam
Journal:  Transl Androl Urol       Date:  2019-12

Review 10.  Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset.

Authors:  Woonyoung Choi; Andrea Ochoa; David J McConkey; Mattias Aine; Mattias Höglund; William Y Kim; Francisco X Real; Anne E Kiltie; Ian Milsom; Lars Dyrskjøt; Seth P Lerner
Journal:  Eur Urol       Date:  2017-03-30       Impact factor: 20.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.